Shafic Makumbi

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 137 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

Anna Turkova, Ellen White, Cissy Kityo et al. · UCL Discovery (University College London) · 2021 · 103 citations

Pharmacy, Pediatrics, Pharmacotherapy +16

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

Pauline Bollen, Cecilia L. Moore, Hilda Mujuru et al. · The Lancet HIV · 2020 · 49 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Hylke Waalewijn, Man K. Chan, Pauline Bollen et al. · The Lancet HIV · 2022 · 38 citations · Full text

Pharmacy, Pediatrics, Pharmacokinetics +14

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Amuge, Abbas Lugemwa, Ben Wynne et al. · The Lancet HIV · 2022 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pediatrics +15